FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207568> ?p ?o ?g. }

• W4387207568 endingPage "S172" @default.
• W4387207568 startingPage "S171" @default.
• W4387207568 abstract "It is unknown whether the use of dual immune-checkpoint inhibition (D-ICI) combined with stereotactic radiosurgery (SRS) affects local control of brain metastases (BMs). We sought to characterize the efficacy of SRS and D-ICI in patients with BMs in a large, single-institution cohort.Patients with melanoma and non-small cell lung cancer (NSCLC) BMs treated with SRS from January 1, 2016 to August 1, 2022 were evaluated. Patients were stratified by treatment with D-ICI versus single ICI (S-ICI). Concurrent ICI was defined as ICI given within four weeks of SRS. Local recurrence (LR), intracranial progression (IP), and overall survival (OS) were estimated using competing risk and Kaplan-Meier analyses. IP included both local and distant intracranial recurrence.One thousand seven hundred four SRS-treated BMs from 288 patients met inclusion criteria. 55% of patients were symptomatic from their BMs at presentation. Median age, KPS, number of lesions, and SRS courses were 64 (Q1Q3:56-70.5), 90 (80-90), 2 (1-4), and 1 (1-2), respectively. One hundred twenty-eight (44%) melanoma and 160 (56%) NSCLC patients were included. 82 (28.5%), 129 (44.8%), and 77 (26.7%) patients were treated with D-ICI, S-ICI, or SRS alone. Median SRS dose, fractions, and PTV were 20 (Q1Q3:20-25), 1 (1-5), and 0.3cc3 (0.1-1.2). The median follow-up was 14.3 months. One hundred twenty-seven (7.45%) BMs recurred post-SRS and the median time to LR was 4.8 months (Q1Q3:3.0-9.2). On competing risk analysis, LR was significantly reduced with D-ICI (HR: 0.452, p = 0.0024), but not with S-ICI (HR: 0.693, p = 0.0596) compared to SRS alone. The 1-year LR was 3.77% (95% CI = 2.19-6.00), 6.8% (5.19-8.70), and 8.96% (6.48-11.93) with D-ICI, S-ICI, and SRS alone. The median time to IP was 4.1 months (Q1Q3 = 2.9-9.5). On competing risk analysis, IP was significantly reduced with D-ICI (HR = 0.638, p = 0.031), but not with S-ICI (HR = 0.756, p = 0.106) compared to SRS alone. 1-year IP was 40.05% (95% CI = 29.14-50.70), 51.86% (42.78-60.19), and 58.49% (46.30-68.84) with D-ICI, S-ICI, and SRS alone. Concurrent delivery of D-ICI and SRS significantly reduced IP (HR = 0.463, p = 0.0071), whereas other combinations of timing and ICI did not reach significance. Median OS was 11.9 months after SRS. On Kaplan Meier analysis, OS was significantly improved with D-ICI (HR = 0.616, 95% CI = 0.412-0.923, p = 0.019), but not with S-ICI (HR = 0.877, 95% CI = 0.633-1.217, p = 0.433) compared to SRS alone. Hospitalizations (p = 0.021) and immune-related adverse events (irAEs) (p<0.001) were increased with D-ICI. Any grade radiation necrosis (RN) was also increased with D-ICI (p = 0.013), but neurologic adverse events were comparable across cohorts (p = 0.572).D-ICI combined with SRS was associated with improved local control, intracranial control, and overall survival compared to SRS alone, whereas S-ICI was not associated with an improvement in these outcomes. However, D-ICI was also associated with increased risks of irAEs and RN." @default.
• W4387207568 created "2023-09-30" @default.
• W4387207568 creator A5007348475 @default.
• W4387207568 creator A5015952087 @default.
• W4387207568 creator A5039317115 @default.
• W4387207568 creator A5040514157 @default.
• W4387207568 creator A5045590924 @default.
• W4387207568 creator A5049734695 @default.
• W4387207568 creator A5055290660 @default.
• W4387207568 creator A5070881158 @default.
• W4387207568 creator A5073918991 @default.
• W4387207568 creator A5080087603 @default.
• W4387207568 creator A5085372530 @default.
• W4387207568 creator A5085548897 @default.
• W4387207568 creator A5090477926 @default.
• W4387207568 creator A5090769354 @default.
• W4387207568 date "2023-10-01" @default.
• W4387207568 modified "2023-10-16" @default.
• W4387207568 title "Intracranial Control with Combined Dual Immune-Checkpoint Blockade and SRS for Melanoma and NSCLC Brain Metastases" @default.
• W4387207568 doi "https://doi.org/10.1016/j.ijrobp.2023.06.637" @default.
• W4387207568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784428" @default.
• W4387207568 hasPublicationYear "2023" @default.
• W4387207568 type Work @default.
• W4387207568 citedByCount "0" @default.
• W4387207568 crossrefType "journal-article" @default.
• W4387207568 hasAuthorship W4387207568A5007348475 @default.
• W4387207568 hasAuthorship W4387207568A5015952087 @default.
• W4387207568 hasAuthorship W4387207568A5039317115 @default.
• W4387207568 hasAuthorship W4387207568A5040514157 @default.
• W4387207568 hasAuthorship W4387207568A5045590924 @default.
• W4387207568 hasAuthorship W4387207568A5049734695 @default.
• W4387207568 hasAuthorship W4387207568A5055290660 @default.
• W4387207568 hasAuthorship W4387207568A5070881158 @default.
• W4387207568 hasAuthorship W4387207568A5073918991 @default.
• W4387207568 hasAuthorship W4387207568A5080087603 @default.
• W4387207568 hasAuthorship W4387207568A5085372530 @default.
• W4387207568 hasAuthorship W4387207568A5085548897 @default.
• W4387207568 hasAuthorship W4387207568A5090477926 @default.
• W4387207568 hasAuthorship W4387207568A5090769354 @default.
• W4387207568 hasConcept C121608353 @default.
• W4387207568 hasConcept C126322002 @default.
• W4387207568 hasConcept C141071460 @default.
• W4387207568 hasConcept C143998085 @default.
• W4387207568 hasConcept C2776256026 @default.
• W4387207568 hasConcept C2777658100 @default.
• W4387207568 hasConcept C2778164965 @default.
• W4387207568 hasConcept C2779013556 @default.
• W4387207568 hasConcept C2780387249 @default.
• W4387207568 hasConcept C502942594 @default.
• W4387207568 hasConcept C509974204 @default.
• W4387207568 hasConcept C71924100 @default.
• W4387207568 hasConcept C72563966 @default.
• W4387207568 hasConceptScore W4387207568C121608353 @default.
• W4387207568 hasConceptScore W4387207568C126322002 @default.
• W4387207568 hasConceptScore W4387207568C141071460 @default.
• W4387207568 hasConceptScore W4387207568C143998085 @default.
• W4387207568 hasConceptScore W4387207568C2776256026 @default.
• W4387207568 hasConceptScore W4387207568C2777658100 @default.
• W4387207568 hasConceptScore W4387207568C2778164965 @default.
• W4387207568 hasConceptScore W4387207568C2779013556 @default.
• W4387207568 hasConceptScore W4387207568C2780387249 @default.
• W4387207568 hasConceptScore W4387207568C502942594 @default.
• W4387207568 hasConceptScore W4387207568C509974204 @default.
• W4387207568 hasConceptScore W4387207568C71924100 @default.
• W4387207568 hasConceptScore W4387207568C72563966 @default.
• W4387207568 hasIssue "2" @default.
• W4387207568 hasLocation W43872075681 @default.
• W4387207568 hasLocation W43872075682 @default.
• W4387207568 hasOpenAccess W4387207568 @default.
• W4387207568 hasPrimaryLocation W43872075681 @default.
• W4387207568 hasRelatedWork W2017442716 @default.
• W4387207568 hasRelatedWork W2158065710 @default.
• W4387207568 hasRelatedWork W2376213003 @default.
• W4387207568 hasRelatedWork W2611009552 @default.
• W4387207568 hasRelatedWork W2809512087 @default.
• W4387207568 hasRelatedWork W2984792600 @default.
• W4387207568 hasRelatedWork W3007968561 @default.
• W4387207568 hasRelatedWork W3032615723 @default.
• W4387207568 hasRelatedWork W3093597142 @default.
• W4387207568 hasRelatedWork W3161969364 @default.
• W4387207568 hasVolume "117" @default.
• W4387207568 isParatext "false" @default.
• W4387207568 isRetracted "false" @default.
• W4387207568 workType "article" @default.